Full Press Release Details
BERKELEY, CA--(Marketwired - Sep 3, 2015) - Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that the company will participate in two investor conferences next week. Dynavax's presentation at the Newsmakers in the Biotech Industry Conference will occur in New York City on September 10, 2015 at 8:30 a.m. EDT. This presentation will be webcast live. Dynavax will also participate in the FBR Second Annual Healthcare Conference in Boston on September 9th, which will not be webcast.
The live or replayed versions of the webcast of the Newsmakers presentation will be available by visiting the "Investors" section of the Dynavax website or may be reached directly at:
Dynavax, a clinical-stage biopharmaceutical company, uses TLR biology to discover and develop novel vaccines and therapeutics in the areas of infectious and inflammatory diseases and oncology. Dynavax's lead product candidates are HEPLISAV-B , a Phase 3 investigational adult hepatitis B vaccine, and SD-101, an investigational cancer immunotherapeutic currently in several Phase 1/2 studies. For more information visit www.dynavax.com.
Contact Information: Contact:
Chief Financial Officer